Large trees play a vital role in forest carbon stocks, dominating the distribution of community biomass. However, climate change and deforestation are reducing large trees globally, resulting in regional differences in their contribution to carbon stocks. Here, we examined the latitudinal change pattern and drivers of large trees' contributions to stand carbon stocks. Above-ground carbon storage was calculated for 530 plots in old-growth forests across China. Linear regression was used to calculate latitudinal variation in the proportion of above-ground carbon in large trees (i.e., AGC proportion). Variance partitioning and multiple linear regression were used to calculate the relative importance of species diversity, stand structure, functional traits, and environmental factors to AGC proportion. The study found that AGC proportion decreased with increasing latitude, averaging at 64.44 %. Stand structure, particularly the coefficient of variation of DBH, was identified as the key drivers of the AGC proportion. The number of common species (Hill's D) had no direct effect on the AGC proportion, while wood density, maximum tree height, and leaf nitrogen-to‑phosphorus ratio showed negative effects. The mass-ratio effects on AGC proportion were stronger than diversity effects. Climate variables primarily affected the AGC proportion through stand variables. These results indicate that simultaneously managing high diversity and AGC proportion may pose challenges. Moreover, considering the substantial contribution of large trees to carbon stocks, their storage capacity and sensitivity to environmental changes exert significant control over forest carbon cycles. Therefore, preserving and enhancing the carbon sink function of old-growth forests in the face of climate change and disturbance may depend primarily on protecting existing large trees and soon-to-be large-diameter trees.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.scitotenv.2024.170586 | DOI Listing |
Eur Radiol
March 2025
BCLC Group, Radiology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
Objective: In patients at risk of hepatocellular carcinoma (HCC), new focal liver lesions identified at ultrasound screening require further characterization by CT or MRI. If these techniques cannot conclusively characterize a lesion, a biopsy or an alternative imaging modality such as contrast-enhanced ultrasound (CEUS) is considered. We aimed to determine the diagnostic yield of CEUS in a sequential noninvasive diagnostic strategy for solitary nodules ≤ 20 mm detected in cirrhotic patients during US surveillance characterized as inconclusive on MRI.
View Article and Find Full Text PDFTher Adv Med Oncol
February 2025
Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Background: Although the emergence of immunotherapy has benefited patients with advanced gastric cancer (AGC), the magnitude of the benefit among real-world patients with HER2-negative AGC remains unclear.
Objectives: The current study aimed to evaluate the treatment features across various immunotherapy approval periods and investigate the utility of immunotherapy for patients with HER2-negative AGC in daily practice.
Design: Retrospective observational study.
Front Oncol
February 2025
Department of General Surgery, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Aims: This study aims to develop a simple, clinically applicable classification system to predict pCR based on carcinoembryonic antigen (CEA) trajectory during NAC.
Methods: This study included 366 AGC patients who received NAC followed by radical gastrectomy. CEA levels were measured before, during, and after NAC, with changes classified into three trajectory types: Type I (>=80% decline), Type II (>=40% but <80% decline), and Type III (<40% decline or increase).
Nutr Cancer
January 2025
Department of Internal Medicine, Xingtai Medical College, Xingtai, China.
Background: Immunotherapy has become a prevalent strategy in the neoadjuvant treatment of advanced gastric cancer (AGC). This study investigates the predictive value of computed tomography (CT)-derived body composition parameters on the efficacy of neoadjuvant immunotherapy for AGC.
Methods: Data on 103 patients with resectable AGC who received neoadjuvant immunotherapy combined with chemotherapy at a teaching hospital between March 2020 and August 2022 were collected.
Oncologist
December 2024
Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya 484-8681, Japan.
Purpose: Human epidermal growth factor receptor 2 (HER2) status is a critical biomarker in advanced gastric cancer (AGC). While the role of HER2-positive tumors in guiding targeted therapies is well-established, the clinical implications of HER2-low expression, defined as immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization-negative (ISH-negative), remain undetermined. The aim of this study was to investigate the prognostic significance and clinicopathological features of HER2-low AGC.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!